Have a rheumatology question or case for Dr. Cush? Record it here and we'll feature it on an upcoming podcast. Tell us your name and where you practice rheumatology. https://t.co/UMrunimVv6 https://t.co/yZNdnAWCy2

• Submit Podcast Question or Comment | RheumNow

RheumThoughts: Overlap Syndrome with ILD How would you manage a patient with Overlap (anti-synthetase) syndrome, ILD, polyarthritis and myositis? https://t.co/4RyV1zkphe https://t.co/qTZ4JYlJmW

• Overlap Syndrome with ILD | RheumNow

VA (Veterans) study of 531 RA-ILD (among 9,701 incident RA) vs 68,852 matched controls - finds exposure to fire smoke PM2.5 assoc w/ RA-ILD/aOR 1.98 (but not RA). NOx, ozone, and PM10 assoc w/ seroneg. RA risk (aOR 1.16-1.25) . Pollution increases risk of RA & RA-ILD… https://t.co/AuG4rRtx4r https://t.co/XyHtjrSfhi

Network metanalysis of 9 RCTs, 3699 patients looked at small molecule Rx in #PsA. With ACR 50/70, PASI 75, & HAQ-DI @ wk 12-16, UPA was > ADA in PASI75 (RR 1.2); Deucravacitinib > Otezla at HAQ (RR −0.16) no OTHER SIGNIF differences observed https://t.co/T0eMkXrxQX https://t.co/FCkbuhi1ze

• Efficacy and safety of small molecule oral medications for psoriatic arthritis:…

FDA Approves First Generic of GLP-1 Receptor Agonist Victoza (liraglutide injection) to Lower Blood Sugar in Patients with Type 2 Diabetes https://t.co/1BYQFU2PsY https://t.co/jmbS9UDnhI

• FDA Approves First Generic of GLP-1 Receptor Agonist Victoza (liraglutide injec…

GLP-1 Agonists Alleviate Knee Osteoarthritis In October, the NEJM published a randomized clinical trial demonstrating the efficacy of glucagon-like peptide-1 receptor agonists (GLP-1ra) in patients with obesity and knee osteoarthritis. https://t.co/3ETmyFWpWY https://t.co/wn1QDwKi3R

• GLP-1 Agonists Alleviate Knee Osteoarthritis | RheumNow

A Modifiable Vascular Risk in SLE Atherosclerosis progression was more than 2x as common in younger people with SLE than in healthy controls in a prospective study from Greece. https://t.co/zGTGin664D https://t.co/ZO9UlIPNIi

• A Modifiable Vascular Risk in SLE | RheumNow

U.S. overdose deaths far outpace other countries. In 2023 US drug overdoses >100,000 for 3rd year — a >50% jump since 2019. 2022 rate=324/1 million. High rates attributed to fentanyl, polysubstance use, counterfeit pills, variance in state policies on harm reduction… https://t.co/oHtiMytdtR https://t.co/DLFPYEkdRC

Online, lifestyle intervention program shown to have positive long-term effects in 264 patients w/ Inflam Arthritis, OA & FM , even after 2-yrs. Prg focused on nutrition, exercise, relaxation & sleep. Signif reductions in Wt, BMI, and PRO's (pain, Am stiff, fatigue)… https://t.co/vghObYPnvW https://t.co/ZSdFPWel57

Leeds study of 19 pts at-risk for RA (ACPA+ & arthralgia) finds low-diversity gut microbiome & in the 10 mos preceding the transition to RA, microbiome becomes more unstable w/ accumulation of Prevotellaceae, particularly Prevotella copri https://t.co/Va9Z0NWHj9 https://t.co/ciM7QtEF5S

• Dynamics of the gut microbiome in individuals at risk of rheumatoid arthritis: …

Study of 1032 adults > 50 yrs on dialysis compared denosumab vs or oral bisphosphonates. 3 yr results showed compared with oral bisphosphonates, denosumab lowered the risk for fractures by 45% and increased the risk for MACE by 36% https://t.co/aogIFBrccy https://t.co/cnlxt5OEjj

• Cardiovascular Safety and Fracture Prevention Effectiveness of Denosumab Versus…